Petra Verdino, Stacey L Lee, Fariba N Cooper, Steven R Cottle, Patrick F Grealish, Charlie C Hu, Catalina M Meyer, Joanne Lin, Victoria Copeland, Gina Porter, Richard L Schroeder, Tyran D Thompson, Leah L Porras, Asim Dey, Hong Y Zhang, Emily C Beebe, Scot J Matkovich, Tamer Coskun, Aldona M Balciunas, Andrea Ferrante, Robert Siegel, Laurent Malherbe, Nicoletta Bivi, Chad D Paavola, Ryan J Hansen, Matthew M Abernathy, Sylvia O Nwosu, Molly C Carr, Josef G Heuer, Xiaojun Wang
BACKGROUND AND PURPOSE: Chronic heart failure, a progressive disease with limited treatment options currently available, especially in heart failure with preserved ejection fraction (HFpEF), represents an unmet medical need as well as an economic burden. The development of a novel therapeutic to slow or reverse disease progression would be highly impactful to patients and society. Relaxin-2 (relaxin) is a human hormone regulating cardiovascular, renal, and pulmonary adaptations during pregnancy...
August 2023: British Journal of Pharmacology